Explore more publications!

Technology Times Somalia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times Somalia.

September 2025

October 2025

November 2025

Press releases published on November 25, 2025

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

November 25, 2025

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

GlobeNewswire

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée

November 25, 2025

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée

GlobeNewswire

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

November 25, 2025

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

GlobeNewswire

atom11 Wins the AI Innovation Award at Amazon Partner Awards 2025

November 25, 2025

atom11 Wins the AI Innovation Award at Amazon Partner Awards 2025

GlobeNewswire

ACASPRESSO Announces Black Friday Mega Sale on Coffee and Blending Appliances

November 25, 2025

ACASPRESSO Announces Black Friday Mega Sale on Coffee and Blending Appliances

GlobeNewswire

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

November 25, 2025

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

GlobeNewswire

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

November 25, 2025

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

GlobeNewswire